Orelabrutinib Bruton’s tyrosine kinase inhibitor in SLE RCT phase Ib/IIa SRI(4) wk 12 50mg 50% 80mg 61% and 100mg 64% and 37.5% PBO Trend ⬇️ proteinuria, anti-dsDNA & IgG Safety: 3SAEs in OLE group LB0005 @RheumNow #EULAR2022 https://t.co/4r16NTaZvT